Cd105 vioblue

Manufactured by Miltenyi Biotec

Sourced in Germany

CD105-VioBlue is a fluorochrome-conjugated antibody product from Miltenyi Biotec. It is designed for the detection of the CD105 antigen, also known as Endoglin, using flow cytometry or other immunoassay techniques.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

CD105 (27 citations)

4 protocols using cd105 vioblue

Isolation and Culture of Tumor-Derived Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Experimental animals, 20/group, were each implanted in the brain with 1 × 10⁵ U87-eGFP-PLuc, NCH644-eGFP-PLuc or NCH421k-eGFP-PLuc cells. Tumors were extracted and mechanically disaggregated using a scalpel. Single cells were separated from tissue clumps using a cell strainer and incubated with red blood cells lysis buffer during 5 minutes. Individual eGFP expressing tumor cells positive for pericytic and endothelial cell markers were isolated using a fluorescence-activated cell sorter (FACS). Pericyte-like cells were sorted from total cells by selecting eGFP+/CD146+/CD248+ cells with anti CD146-VioBlue (Miltenyi Biotec) and anti CD248-Alexa Fluor 647 (clone B1/35 Beckton Dickinson). Endothelial-like cells were sorted by selecting eGFP+/CD31+/CD105+ cells with anti CD31-APC (Miltenyi Biotec) and CD105-VioBlue (Miltenyi Biotec). Selected positive cells of either type were grown in non-adherent plates with tumorsphere culture media.

Guerra-Rebollo M., Garrido C., Sánchez-Cid L., Soler-Botija C., Meca-Cortés O., Rubio N, & Blanco J. (2019). Targeting of replicating CD133 and OCT4/SOX2 expressing glioma stem cells selects a cell population that reinitiates tumors upon release of therapeutic pressure. Scientific Reports, 9, 9549.

+ Open protocol

+ Expand

Multilineage Antigen Expression in Hematopoietic, Cardiomyocyte, and Endothelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

The expressions of antigens associated with hematopoietic, cardiomyocyte, and endothelial lineages were evaluated. Human control and differentiated CD34⁺ cells were dissociated with 0.25% Trypsin-EDTA (Life Technologies, Courtaboeuf, France) for 4 min at 37 °C, washed, counted, suspended in PBS, and stained for 15 min at room temperature with different combinations of the following mouse anti-human monoclonal antibody surface markers: FITC-CD34 (130-113-178), APC-CD309 (KDR) (130-093-601), CD73-PE (130-112-060), CD133-PE (130-098-826), CD90-PE (130-117-537) (Miltenyi Biotec, Bergisch Gladbach, Germany), CD106-APC (305809) (Biolegend, Amsterdam, The Netherlands), CD105-VioBlue (130-112-320), CD117-PE-Vio770 (130-111-672), CD172a-PE-Vio770 (130-099-793), CD146-PE-Vio770 (130-099-957), CD344-PE-Vio770 (130-106-572), and CD31-APC (130-110-808) (Miltenyi Biotec). The cells were washed and suspended in PBS, and 7AAD was used to discriminate between living and dead cells. The different samples were then analyzed using a FacsCanto II instrument (Becton Dickinson Biosciences, Le Pont de Claix, France).

Aries A., Zanetti C., Hénon P., Drénou B, & Lahlil R. (2023). Deciphering the Cardiovascular Potential of Human CD34+ Stem Cells. International Journal of Molecular Sciences, 24(11), 9551.

+ Open protocol

+ Expand

Neural Crest Cell Characterization

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Five “cluster of differentiation” markers previously identified in our laboratory were used to assess the ability of WT SRCAP and FHS MUT SRCAP lines to make neural crest cells (Prescott et al. 2015 (link)). These markers were CD10 (MME), CD99, CD105 (ENG), CD266 (TNFRSF12A) and CD271 (NGFR, p75) (Miltenyi Biotec). Cells were stained with surface marker antibodies in FACS buffer (5% FBS, 5mM EDTA, 0.1% sodium azide in PBS) and surface expression of each marker was determined using flow cytometry (AriaII SORP and BD Fortessa). All antibodies used (5μL each per sample) for surface marker analysis: CD10-APC, CD24 PerCP-Vio700, CD99-APC-Vio770, CD105-VioBlue, CD266-PE, CD271-PE-Vio770 (Miltenyi).

Greenberg R.S., Long H.K., Swigut T, & Wysocka J. (2019). Single amino acid change underlies distinct roles of H2A.Z subtypes in human syndrome. Cell, 178(6), 1421-1436.e24.

+ Open protocol

+ Expand

Flow Cytometry Immunophenotyping of ASCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

First-passage ASCs were labeled with CD13-APC-Vio700, CD31-APC, CD34-PE, CD45-VioGreen, CD73-PE-Vio770, CD105-VioBlue and CD146-VioBright515, purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Samples were acquired on a four-laser flow cytometry system (BD LSR II, Becton-Dickinson, Franklin Lake, NJ, USA). Fc receptor reagent was added to avoid unspecific labelling of cells via Fc receptors.

Doornaert M., Depypere B., Creytens D., Declercq H., Taminau J., Lemeire K., Monstrey S., Berx G, & Blondeel P. (2019). Human decellularized dermal matrix seeded with adipose-derived stem cells enhances wound healing in a murine model: Experimental study. Annals of Medicine and Surgery, 46, 4-11.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!